Scott Dunseth Myers - Net Worth and Insider Trading
Scott Dunseth Myers Net Worth
The estimated net worth of Scott Dunseth Myers is at least $4 Million dollars as of 2024-04-24. Scott Dunseth Myers is the CEO of Viridian Therapeutics Inc and owns about 259,500 shares of Viridian Therapeutics Inc (VRDN) stock worth over $3 Million. Scott Dunseth Myers is also the President and CEO of Cascadian Therapeutics Inc and owns about 49,716 shares of Cascadian Therapeutics Inc (CASC) stock worth over $498,154. Details can be seen in Scott Dunseth Myers's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Scott Dunseth Myers has not made any transactions after 2023-04-12 and currently still holds the listed stock(s).
Transaction Summary of Scott Dunseth Myers
Scott Dunseth Myers Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Scott Dunseth Myers owns 6 companies in total, including Cartesian Therapeutics Inc (RNAC) , Harpoon Therapeutics Inc (HARP) , and AMAG Pharmaceuticals Inc (AMAG) among others .
Click here to see the complete history of Scott Dunseth Myers’s form 4 insider trades.
Insider Ownership Summary of Scott Dunseth Myers
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| RNAC | Cartesian Therapeutics Inc | 2019-12-23 | director |
| HARP | Harpoon Therapeutics Inc | 2019-02-07 | director |
| AMAG | AMAG Pharmaceuticals Inc | 2020-04-28 | director & President & CEO |
| CASC | Cascadian Therapeutics Inc | 2018-03-09 | director & President and CEO |
| DVAX | Dynavax Technologies Corp | 2021-10-19 | director |
| VRDN | Viridian Therapeutics Inc | 2023-04-12 | director & Chief Executive Officer |
Scott Dunseth Myers Latest Holdings Summary
Scott Dunseth Myers currently owns a total of 2 stocks. Among these stocks, Scott Dunseth Myers owns 259,500 shares of Viridian Therapeutics Inc (VRDN) as of April 12, 2023, with a value of $3 Million and a weighting of 87.28%. Scott Dunseth Myers also owns 49,716 shares of Cascadian Therapeutics Inc (CASC) as of August 11, 2017, with a value of $498,154 and a weighting of 12.72%.
Latest Holdings of Scott Dunseth Myers
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| VRDN | Viridian Therapeutics Inc | 2023-04-12 | 259,500 | 13.17 | 3,417,485 |
| CASC | Cascadian Therapeutics Inc | 2017-08-11 | 49,716 | 10.02 | 498,154 |
Holding Weightings of Scott Dunseth Myers
Scott Dunseth Myers Form 4 Trading Tracker
According to the SEC Form 4 filings, Scott Dunseth Myers has made a total of 2 transactions in Viridian Therapeutics Inc (VRDN) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Viridian Therapeutics Inc is the acquisition of 4,000 shares on April 12, 2023, which cost Scott Dunseth Myers around $101,480.
According to the SEC Form 4 filings, Scott Dunseth Myers has made a total of 0 transactions in Cascadian Therapeutics Inc (CASC) over the past 5 years. The most-recent trade in Cascadian Therapeutics Inc is the acquisition of 5,500 shares on August 11, 2017, which cost Scott Dunseth Myers around $20,570.
Insider Trading History of Scott Dunseth Myers
- 1
Scott Dunseth Myers Trading Performance
GuruFocus tracks the stock performance after each of Scott Dunseth Myers's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Scott Dunseth Myers is 5.56%. GuruFocus also compares Scott Dunseth Myers's trading performance to market benchmark return within the same time period. The performance of stocks bought by Scott Dunseth Myers within 3 months outperforms 3 times out of 8 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Scott Dunseth Myers's insider trading performs compared to the benchmark.
Performance of Scott Dunseth Myers
Average Return
8.21%
Outperforming Transactions
33%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 1.63 | 5.56 | 3.07 | 8.21 | ||
| Relative Return to S&P 500(%) | -0.6 | -0.25 | -5.36 | -13.76 |
Scott Dunseth Myers Ownership Network
Ownership Network List of Scott Dunseth Myers
Ownership Network Relation of Scott Dunseth Myers
Scott Dunseth Myers Owned Company Details
What does Cartesian Therapeutics Inc do?
Who are the key executives at Cartesian Therapeutics Inc?
Scott Dunseth Myers is the director of Cartesian Therapeutics Inc. Other key executives at Cartesian Therapeutics Inc include Chief Medical Officer Peter G Traber , director & President & CEO Carsten Brunn , and Chief Scientific Officer Takashi Kei Kishimoto .
Cartesian Therapeutics Inc (RNAC) Insider Trades Summary
Over the past 18 months, Scott Dunseth Myers made no insider transaction in Cartesian Therapeutics Inc (RNAC). Other recent insider transactions involving Cartesian Therapeutics Inc (RNAC) include a net purchase of 1,223,316 shares made by Timothy A Springer , a net sale of 48,524 shares made by Carsten Brunn , and a net sale of 12,349 shares made by Peter G Traber .
In summary, during the past 3 months, insiders sold 0 shares of Cartesian Therapeutics Inc (RNAC) in total and bought 40,777 shares, with a net purchase of 40,777 shares. During the past 18 months, 2,681 shares of Cartesian Therapeutics Inc (RNAC) were sold and 40,777 shares were bought by its insiders, resulting in a net purchase of 38,096 shares.
Cartesian Therapeutics Inc (RNAC)'s detailed insider trading history can be found in Insider Trading Tracker table.
Cartesian Therapeutics Inc Insider Transactions
Scott Dunseth Myers Mailing Address
Above is the net worth, insider trading, and ownership report for Scott Dunseth Myers. You might contact Scott Dunseth Myers via mailing address: C/o Cascadian Therapeutics, Inc., 3101 Western Ave., Suite 600, Seattle Wa 98121.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
